About Vivimed Labs Limited
Data last updated: 29 September 2026
Vivimed Labs Limited is a public limited company based in Karnataka., Karnataka, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It specialises in personal care and skincare products, a part of the broader FMCG sector. Incorporated on 22 September 1988, the company has been in operation for over 38 years.
Registered with ROC Bangalore under CIN L02411KA1988PLC009465. Listed on BSE: 532660 and NSE: VIVIMEDLAB.
Capital: an authorised share capital of ₹111 Cr and a paid-up capital of ₹16.58 Cr. Formerly known as Emgi Pharmaceuticals & Chemicals Limited and Emgi Pharmaceuticals & Chemicals Private Limited. It is led by directors including Manohar Rao Varalwar and Sandeep Varalwar.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No. 78 – A Kolhar Industrial Area Bidar, Karnataka., Karnataka, India – 585403.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹69.99 Cr, a decline of 39.8% compared to the previous year.
The company has a workforce of approximately 59 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Vivimed Labs. As per MCA filings, the company has open charges of ₹932.51 Cr and satisfied charges of ₹791.99 Cr on record.
The company is undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional, and the company may not be able to independently enter into new commitments. The last known website on record is vivimedlabs.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressPlot No. 78 – A Kolhar Industrial Area Bidar, Karnataka., Karnataka, India – 585403
- IndustryFMCG, Personal Care & Skincare Products
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Vivimed Labs Limited
Vivimed Labs Limited has undergone 2 name changes throughout its history. The company was previously known as Emgi Pharmaceuticals & Chemicals Limited, and Emgi Pharmaceuticals & Chemicals Private Limited. The current legal name is Vivimed Labs Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Vivimed Labs Limited | Current |
| Emgi Pharmaceuticals & Chemicals Limited | Previous |
| Emgi Pharmaceuticals & Chemicals Private Limited | Previous |
Associated Brands with Vivimed Labs Limited
Vivimed Labs Limited operates one associated brand: Vivimed Labs. These brands represent Vivimed Labs Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients, formulations, and specialty chemicals are manufactured. | vivimedlabs.com |
Competitors & Alternatives of Vivimed Labs Limited
Brands and companies operating in the same space as Vivimed Labs Limited include Concord Biotech, Almac Group, Indoco Remedies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
 Concord Biotech | APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
 Almac Group | Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
 Indoco Remedies | APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
 Pharmaceutics International | Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
 Aurobindo Pharma | Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
 Seqens | Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
 Asymchem | APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
 Aptuit | Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
 Continuus Pharma | MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Vivimed Labs Limited
Vivimed Labs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Vivimed Labs Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Vivimed Labs Limited
Vivimed Labs Limited is audited by SVRL & Co Chartered Accountants for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| SVRL & Co Chartered Accountants | Locked | Locked | Locked |
Complete auditor history for Vivimed Labs Limited
Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Vivimed Labs Limited
Vivimed Labs Limited is currently managed by 6 directors, with 25 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manohar Rao Varalwar | Whole-Time Director | 14 Aug 2015 | 11 Years 1 Months | As last reported |
| Sandeep Varalwar Also directs: B B R Projects Private Limited | Whole-Time Director | 27 Sep 2008 | 18 Years 0 Months | As last reported |
| Santosh Varalwar Also directs: B B R Projects Private Limited, Uquifa India Private Limited, Kreative Hosts Atria Private Limited and 2 more | Managing Director | 09 Nov 1989 | 36 Years 10 Months | As last reported |
| Aparna Bidarkar Also directs: Finoso Pharma Private Limited, Lattice Projex Private Limited | Director | 14 Feb 2022 | 4 Years 7 Months | As last reported |
| Siva Prasad Jarugula | Director | 11 Dec 2024 | 1 Years 9 Months | As last reported |
| Subbarathnamma Palepu Also directs: Ahlada Engineers Limited, Gss Infotech Limited, More Agrisupplies & Services Private Limited and 3 more | Director | 11 Dec 2024 | 1 Years 9 Months | As last reported |
Financials of Vivimed Labs Limited FY 2025-26 filings available
Vivimed Labs Limited reported revenue of ₹69.99 Cr (down 39.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 69.99 | 116 | 149 | 187 | 237 | 861 | 1,059 |
| Revenue growth | +72.1% | -29.0% | -51.4% | +52.6% | -70.5% | -20.9% | -7.6% |
| EBITDA | (152) | (13.01) | (32.88) | (187) | (7.85) | 31.51 | 10.24 |
| EBITDA margin | -217.8% | -11.2% | -22.1% | -99.9% | -3.3% | +3.7% | +1.0% |
| Profit before tax | (176) | (31.84) | (45.82) | (331) | (64.85) | (69.87) | (109) |
| Net profit | (176) | (31.96) | (45.44) | (329) | (67.67) | (71.90) | (109) |
| Net profit margin | -252.1% | -27.5% | -30.5% | -175.6% | -28.5% | -8.4% | -10.3% |
| EPS (₹) | (20.53) | (3.85) | (5.48) | (39.62) | (8.16) | (8.67) | (13.16) |
| Balance sheet | |||||||
| Total assets | - | 817 | 845 | 878 | 1,179 | 1,207 | 1,912 |
| Net worth | - | (35.17) | (5.46) | 39.42 | 364 | 432 | 835 |
| Total debt | - | 376 | 377 | 379 | 359 | 326 | 943 |
| Cash & bank | - | 0.71 | 2.03 | 3.76 | 7.18 | 6.43 | 50.49 |
| Net working capital | - | 232 | 246 | 231 | 432 | 455 | 677 |
| Cash flow | |||||||
| Cash from operations | - | (1.75) | (23.99) | 35.32 | 27.54 | 567 | 79.56 |
| Cash from investing | - | (4.53) | 28.29 | (4.96) | (16.41) | 404 | (196) |
| Cash from financing | - | 4.96 | (6.03) | (33.78) | (10.38) | (1,015) | 72.44 |
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.00 | 15.99 | 20.61 | 21.39 | 25.61 | 36.51 | 24.77 | 29.37 |
| Revenue growth (YoY) | -53.1% | -56.2% | -16.8% | -27.2% | -33.7% | -11.9% | -26.4% | -16.9% |
| Other income | 5.75 | 0.00 | 0.21 | 0.38 | 4.22 | 0.07 | 0.03 | 0.06 |
| EBITDA | (140) | (10.92) | (0.96) | (0.28) | (2.47) | 1.06 | (0.64) | (11.00) |
| EBITDA margin | -1169.0% | -68.3% | -4.7% | -1.3% | -9.6% | +2.9% | -2.6% | -37.5% |
| Depreciation | 11.51 | 4.63 | 4.90 | 5.01 | 5.50 | 6.62 | 4.10 | 4.01 |
| Interest | 0.95 | 1.00 | 1.66 | 0.58 | 1.74 | 0.48 | 0.43 | 0.30 |
| Profit before tax | (147) | (16.55) | (7.31) | (5.49) | (5.49) | (5.97) | (5.14) | (15.25) |
| Tax | 0.14 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 |
| Net profit | (147) | (16.55) | (7.31) | (5.49) | (5.61) | (5.97) | (5.14) | (15.25) |
| EPS (₹) | (17.22) | (1.94) | (0.85) | (0.64) | (0.68) | (0.70) | (0.60) | (1.78) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 55.78 | 104 | 137 | 177 | 218 | 210 | 277 |
| Revenue growth | +74.3% | -30.5% | -53.4% | +60.4% | +24.8% | -25.3% | +32.3% |
| EBITDA | (150) | (14.50) | (33.14) | (188) | (9.04) | 27.84 | 32.73 |
| EBITDA margin | -269.1% | -14.0% | -24.2% | -106.3% | -4.1% | +13.3% | +11.8% |
| Profit before tax | (172) | (31.48) | (44.39) | (330) | (64.94) | (23.51) | (20.74) |
| Net profit | (172) | (31.48) | (44.39) | (328) | (67.76) | (23.28) | (12.30) |
| Net profit margin | -307.7% | -30.4% | -32.5% | -185.5% | -31.0% | -11.1% | -4.5% |
| EPS (₹) | (19.98) | (3.80) | (5.35) | (39.56) | (8.17) | (2.81) | (2.31) |
| Balance sheet | |||||||
| Total assets | - | 548 | 593 | 689 | 991 | 1,023 | 993 |
| Net worth | - | 58.49 | 89.41 | 133 | 457 | 524 | 554 |
| Total debt | - | 375 | 375 | 377 | 357 | 323 | 304 |
| Cash & bank | - | 0.29 | 1.14 | 3.35 | 6.78 | 6.02 | 11.09 |
| Net working capital | - | 166 | 197 | 173 | 372 | 395 | 488 |
| Cash flow | |||||||
| Cash from operations | - | 5.73 | (96.52) | 32.87 | 25.31 | 180 | 75.02 |
| Cash from investing | - | (4.06) | 99.83 | (1.60) | (11.34) | (138) | 3.32 |
| Cash from financing | - | (2.53) | (5.51) | (34.70) | (13.21) | (46.40) | (91.42) |
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.55 | 11.63 | 18.66 | 17.94 | 22.58 | 34.23 | 22.16 | 24.64 |
| Revenue growth (YoY) | -66.6% | -66.0% | -15.8% | -27.2% | -38.0% | -7.8% | -26.8% | -25.3% |
| Other income | 0.00 | 0.00 | 0.16 | 0.36 | 4.15 | 0.00 | 0.03 | 0.00 |
| Total expenses | 145 | 22.85 | 19.98 | 18.48 | 25.06 | 34.41 | 22.95 | 35.71 |
| EBITDA | (137) | (11.22) | (1.32) | (0.54) | (2.48) | (0.18) | (0.79) | (11.07) |
| EBITDA margin | -1814.7% | -96.5% | -7.1% | -3.0% | -11.0% | -0.5% | -3.6% | -44.9% |
| Depreciation | 4.31 | 4.40 | 4.68 | 4.80 | 4.61 | 6.37 | 3.86 | 3.79 |
| Interest | 0.79 | 0.94 | 1.60 | 0.52 | 1.48 | 0.43 | 0.37 | 0.25 |
| Profit before tax | (142) | (16.56) | (7.44) | (5.50) | (4.42) | (6.98) | (4.99) | (15.11) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.00 | 15.99 | 20.61 | 21.39 | 25.61 | 36.51 | 24.77 | 29.37 |
| Revenue growth (YoY) | -53.1% | -56.2% | -16.8% | -27.2% | -33.7% | -11.9% | -26.4% | -16.9% |
| Other income | 5.75 | 0.00 | 0.21 | 0.38 | 4.22 | 0.07 | 0.03 | 0.06 |
| EBITDA | (140) | (10.92) | (0.96) | (0.28) | (2.47) | 1.06 | (0.64) | (11.00) |
| EBITDA margin | -1169.0% | -68.3% | -4.7% | -1.3% | -9.6% | +2.9% | -2.6% | -37.5% |
| Depreciation | 11.51 | 4.63 | 4.90 | 5.01 | 5.50 | 6.62 | 4.10 | 4.01 |
| Interest | 0.95 | 1.00 | 1.66 | 0.58 | 1.74 | 0.48 | 0.43 | 0.30 |
| Profit before tax | (147) | (16.55) | (7.31) | (5.49) | (5.49) | (5.97) | (5.14) | (15.25) |
| Tax | 0.14 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 |
| Net profit | (147) | (16.55) | (7.31) | (5.49) | (5.61) | (5.97) | (5.14) | (15.25) |
| EPS (₹) | (17.22) | (1.94) | (0.85) | (0.64) | (0.68) | (0.70) | (0.60) | (1.78) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 69.99 | 116 | 149 | 187 | 237 | 861 | 1,059 |
| Revenue growth | +72.1% | -29.0% | -51.4% | +52.6% | -70.5% | -20.9% | -7.6% |
| Other income | 6.32 | 4.37 | 9.98 | 0.97 | 1.27 | 9.82 | 8.26 |
| Total expenses | 222 | 129 | 182 | 374 | 245 | 830 | 1,049 |
| Employee cost | 0.00 | 28.39 | 34.16 | 32.67 | 36.22 | 190 | 233 |
| EBITDA | (152) | (13.01) | (32.88) | (187) | (7.85) | 31.51 | 10.24 |
| EBITDA margin | -217.8% | -11.2% | -22.1% | -99.9% | -3.3% | +3.7% | +1.0% |
| Depreciation | 26.05 | 20.22 | 19.94 | 108 | 18.28 | 55.50 | 66.95 |
| Interest | 4.17 | 2.98 | 2.98 | 36.23 | 39.99 | 55.70 | 61.03 |
| Profit before tax | (176) | (31.84) | (45.82) | (331) | (64.85) | (69.87) | (109) |
| Tax | 0.14 | 0.12 | (0.38) | (2.12) | 2.82 | 2.03 | (0.36) |
| Net profit | (176) | (31.96) | (45.44) | (329) | (67.67) | (71.90) | (109) |
| Net profit margin | -252.1% | -27.5% | -30.5% | -175.6% | -28.5% | -8.4% | -10.3% |
| EPS (₹) | (20.53) | (3.85) | (5.48) | (39.62) | (8.16) | (8.67) | (13.16) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 16.58 | 16.58 | 16.58 | 16.58 | 16.58 | 342 |
| Reserves & surplus | - | (51.75) | (22.04) | 22.84 | 348 | 415 | 493 |
| Shareholders' funds (net worth) | - | (35.17) | (5.46) | 39.42 | 364 | 432 | 835 |
| Minority interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | - | 313 | 314 | 317 | 298 | 269 | 833 |
| Unsecured loans | - | 63.32 | 63.32 | 61.98 | 60.61 | 56.27 | 110 |
| Total debt | - | 376 | 377 | 379 | 359 | 326 | 943 |
| Total liabilities | - | 817 | 845 | 878 | 1,179 | 1,207 | 1,912 |
| Assets | |||||||
| Gross block | - | 752 | 742 | 740 | 802 | 766 | 1,274 |
| Net block | - | 408 | 418 | 436 | 520 | 502 | 1,045 |
| Capital work in progress | - | 17.11 | 20.65 | 20.67 | 40.03 | 60.12 | 89.28 |
| Investments | - | 168 | 168 | 199 | 199 | 199 | 85.71 |
| Inventories | - | 58.76 | 64.06 | 161 | 241 | 256 | 502 |
| Sundry debtors | - | 74.11 | 82.82 | 74.16 | 87.36 | 108 | 249 |
| Cash & bank balances | - | 0.71 | 2.03 | 3.76 | 7.18 | 6.43 | 50.49 |
| Loans & advances | - | 194 | 194 | 181 | 172 | 159 | 174 |
| Total current assets | - | 328 | 343 | 420 | 507 | 529 | 975 |
| Total current liabilities | - | 95.48 | 96.97 | 189 | 75.50 | 73.25 | 298 |
| Net working capital | - | 232 | 246 | 231 | 432 | 455 | 677 |
| Total assets | - | 817 | 845 | 878 | 1,179 | 1,207 | 1,912 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 2.03 | 3.76 | 7.18 | 6.43 | 50.49 | 94.50 |
| Net cash from operating activities | - | (1.75) | (23.99) | 35.32 | 27.54 | 567 | 79.56 |
| Net cash from investing activities | - | (4.53) | 28.29 | (4.96) | (16.41) | 404 | (196) |
| Net cash from financing activities | - | 4.96 | (6.03) | (33.78) | (10.38) | (1,015) | 72.44 |
| Net change in cash | - | (1.32) | (1.74) | (3.42) | 0.75 | (44.06) | (44.02) |
| Closing cash | - | 0.71 | 2.03 | 3.76 | 7.18 | 6.43 | 50.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -39.8% | -22.0% | -20.3% | -21.2% | -72.5% | -18.6% | -19.5% |
| EBITDA growth | -1071.6% | +60.4% | +82.4% | -2282.0% | - | +207.7% | -94.3% |
| PBT growth | -453.8% | +30.5% | +86.1% | -409.9% | +7.2% | +36.2% | - |
| Net income growth | -452.2% | +29.7% | +86.2% | -385.5% | +5.9% | +34.1% | - |
| Revenue CAGR (3Y) | -28.0% | -21.2% | -44.3% | -43.9% | -43.5% | -10.1% | -10.2% |
| EBITDA CAGR (3Y) | -6.6% | +18.3% | - | - | - | -47.3% | -70.6% |
| Profitability & leverage | |||||||
| Net income margin | -252.1% | -27.5% | -30.5% | -175.6% | -28.5% | -8.4% | -10.3% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | -2.2% | -0.9% | -2.6% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | -18.8% | -16.6% | -20.8% |
| Debt / equity | - | 0.00 | 0.00 | 2.25 | 0.95 | 1.07 | 1.11 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.38 | 0.17 | 0.44 | 0.53 |
| Interest cover | -2.34 | -8.97 | -5.64 | -12.26 | -153.04 | -232.18 | -107.62 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.16 | 0.21 | 0.26 | 0.32 | 0.88 | 0.90 |
| Inventory turnover | - | 1.89 | 1.33 | 0.93 | 0.96 | 2.27 | 1.99 |
| Debtors turnover | - | 1.48 | 1.90 | 2.32 | 2.44 | 4.83 | 3.50 |
| EPS (₹) | (20.53) | (3.85) | (5.48) | (39.62) | (8.16) | (8.67) | (13.16) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | (8.82) | (5.24) | 0.17 | 39.35 | 47.47 | 56.85 |
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.55 | 11.63 | 18.66 | 17.94 | 22.58 | 34.23 | 22.16 | 24.64 |
| Revenue growth (YoY) | -66.6% | -66.0% | -15.8% | -27.2% | -38.0% | -7.8% | -26.8% | -25.3% |
| Other income | 0.00 | 0.00 | 0.16 | 0.36 | 4.15 | 0.00 | 0.03 | 0.00 |
| Total expenses | 145 | 22.85 | 19.98 | 18.48 | 25.06 | 34.41 | 22.95 | 35.71 |
| EBITDA | (137) | (11.22) | (1.32) | (0.54) | (2.48) | (0.18) | (0.79) | (11.07) |
| EBITDA margin | -1814.7% | -96.5% | -7.1% | -3.0% | -11.0% | -0.5% | -3.6% | -44.9% |
| Depreciation | 4.31 | 4.40 | 4.68 | 4.80 | 4.61 | 6.37 | 3.86 | 3.79 |
| Interest | 0.79 | 0.94 | 1.60 | 0.52 | 1.48 | 0.43 | 0.37 | 0.25 |
| Profit before tax | (142) | (16.56) | (7.44) | (5.50) | (4.42) | (6.98) | (4.99) | (15.11) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 55.78 | 104 | 137 | 177 | 218 | 210 | 277 |
| Revenue growth | +74.3% | -30.5% | -53.4% | +60.4% | +24.8% | -25.3% | +32.3% |
| Other income | 0.51 | 4.19 | 9.57 | 0.24 | 1.26 | 6.08 | 6.54 |
| Total expenses | 206 | 118 | 170 | 365 | 227 | 182 | 244 |
| Employee cost | 0.00 | 23.04 | 29.45 | 29.67 | 31.68 | 26.45 | 31.87 |
| EBITDA | (150) | (14.50) | (33.14) | (188) | (9.04) | 27.84 | 32.73 |
| EBITDA margin | -269.1% | -14.0% | -24.2% | -106.3% | -4.1% | +13.3% | +11.8% |
| Depreciation | 18.19 | 18.63 | 18.41 | 107 | 17.45 | 15.80 | 16.57 |
| Interest | 3.86 | 2.54 | 2.41 | 35.55 | 39.71 | 41.63 | 43.44 |
| Profit before tax | (172) | (31.48) | (44.39) | (330) | (64.94) | (23.51) | (20.74) |
| Tax | 0.00 | 0.00 | 0.00 | (2.12) | 2.82 | (0.23) | (1.57) |
| Net profit | (172) | (31.48) | (44.39) | (328) | (67.76) | (23.28) | (12.30) |
| Net profit margin | -307.7% | -30.4% | -32.5% | -185.5% | -31.0% | -11.1% | -4.5% |
| EPS (₹) | (19.98) | (3.80) | (5.35) | (39.56) | (8.17) | (2.81) | (2.31) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 16.58 | 16.58 | 16.58 | 16.58 | 16.58 | 16.58 |
| Reserves & surplus | - | 41.91 | 72.83 | 117 | 441 | 508 | 537 |
| Shareholders' funds (net worth) | - | 58.49 | 89.41 | 133 | 457 | 524 | 554 |
| Secured loans | - | 312 | 312 | 315 | 296 | 267 | 200 |
| Unsecured loans | - | 63.32 | 63.32 | 61.98 | 60.61 | 56.27 | 104 |
| Total debt | - | 375 | 375 | 377 | 357 | 323 | 304 |
| Total liabilities | - | 548 | 593 | 689 | 991 | 1,023 | 993 |
| Assets | |||||||
| Gross block | - | 514 | 507 | 505 | 566 | 536 | 463 |
| Net block | - | 315 | 326 | 343 | 429 | 416 | 356 |
| Capital work in progress | - | 17.11 | 20.65 | 20.67 | 40.03 | 58.45 | 69.77 |
| Investments | - | 58.78 | 58.78 | 161 | 161 | 161 | 87.50 |
| Inventories | - | 56.50 | 62.77 | 78.31 | 239 | 254 | 263 |
| Sundry debtors | - | 45.80 | 59.54 | 50.30 | 63.39 | 76.70 | 89.67 |
| Cash & bank balances | - | 0.29 | 1.14 | 3.35 | 6.78 | 6.02 | 11.09 |
| Loans & advances | - | 145 | 152 | 139 | 133 | 122 | 190 |
| Total current assets | - | 248 | 276 | 271 | 442 | 459 | 554 |
| Total current liabilities | - | 81.70 | 79.02 | 97.83 | 69.49 | 63.73 | 65.29 |
| Net working capital | - | 166 | 197 | 173 | 372 | 395 | 488 |
| Total assets | - | 548 | 593 | 689 | 991 | 1,023 | 993 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 1.14 | 3.35 | 6.78 | 6.02 | 11.09 | 24.16 |
| Net cash from operating activities | - | 5.73 | (96.52) | 32.87 | 25.31 | 180 | 75.02 |
| Net cash from investing activities | - | (4.06) | 99.83 | (1.60) | (11.34) | (138) | 3.32 |
| Net cash from financing activities | - | (2.53) | (5.51) | (34.70) | (13.21) | (46.40) | (91.42) |
| Net change in cash | - | (0.86) | (2.20) | (3.43) | 0.76 | (5.07) | (13.07) |
| Closing cash | - | 0.29 | 1.14 | 3.35 | 6.78 | 6.02 | 11.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -46.2% | -24.3% | -22.6% | -19.0% | +4.0% | -24.1% | +9.9% |
| EBITDA growth | -935.0% | +56.3% | +82.4% | -1978.5% | - | -14.9% | -51.5% |
| PBT growth | -445.2% | +29.1% | +86.6% | -408.4% | -176.2% | -13.4% | - |
| Net income growth | -445.2% | +29.1% | +86.5% | -384.1% | -191.1% | -89.3% | - |
| Revenue CAGR (3Y) | -31.9% | -22.0% | -13.3% | -13.9% | -4.6% | -7.0% | -21.4% |
| EBITDA CAGR (3Y) | -7.2% | +17.1% | - | - | - | -29.2% | -49.3% |
| Profitability & leverage | |||||||
| Net income margin | -307.7% | -30.4% | -32.5% | -185.5% | -31.0% | -11.1% | -6.9% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | -2.6% | +1.9% | +3.0% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | -15.0% | -4.7% | -2.3% |
| Debt / equity | - | 10.44 | 5.13 | 1.43 | 0.75 | 0.63 | 0.62 |
| Long-term debt / equity | - | 1.76 | 0.85 | 0.24 | 0.13 | 0.12 | 0.15 |
| Interest cover | -2.29 | -7.67 | -4.68 | -12.06 | -149.91 | 345.76 | 268.81 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.22 | 0.29 | 0.36 | 0.43 | 0.46 | 0.64 |
| Inventory turnover | - | 1.74 | 1.94 | 1.11 | 0.89 | 0.81 | 1.01 |
| Debtors turnover | - | 1.97 | 2.49 | 3.11 | 3.12 | 2.53 | 2.89 |
| EPS (₹) | (19.98) | (3.80) | (5.35) | (39.56) | (8.17) | (2.81) | (2.31) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 2.47 | 6.20 | 11.50 | 50.57 | 58.67 | 62.22 |
Shareholding Pattern of Vivimed Labs Limited
As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 7.60%, foreign institutional investors hold 1.60%, domestic institutional investors hold 0.20%, retail and other public shareholders hold 90.70% of Vivimed Labs Limited.
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | |
|---|---|---|---|---|
| Promoters | 7.60% | 7.80% | 7.80% | 7.80% |
| Public | 92.40% | 92.20% | 92.20% | 92.20% |
Group Structure of Vivimed Labs Limited
Vivimed Labs Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Vivimed Labs Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Finoso Pharma Private Limited | U24231TG2009PTC064774 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Vivimed Labs Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Dec 2020 | Others | ₹232 Cr | Open |
| 29 Jul 2020 | Others | ₹15 Cr | Open |
| 08 Nov 2017 | State Bank of India | ₹4.5 Cr | Open |
| 02 Apr 2015 | Corporation Bank | ₹16 Lakh | Open |
| 25 Sep 2014 | State Bank of Hyderabad | ₹5.75 Cr | Open |
Total charge records: 46 View all charges
Employees and EPFO Compliance at Vivimed Labs Limited
Vivimed Labs Limited has a workforce of 59 employees as of Apr 05, 2025.
Employee and EPFO history for Vivimed Labs Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Vivimed Labs Limited
GST registrations and filing compliance for Vivimed Labs Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Vivimed Labs Limited
Credit ratings, litigation, and regulatory alerts for Vivimed Labs Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Vivimed Labs Limited
MSME payment history for Vivimed Labs Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Vivimed Labs Limited
Corporate group structure for Vivimed Labs Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Vivimed Labs Limited
MCA filings and documents for Vivimed Labs Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Vivimed Labs Limited
Recent News on Vivimed Labs Limited
Frequently Asked Questions about Vivimed Labs Limited
Vivimed Labs Limited is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Vivimed Labs Limited is a company under insolvency, formerly operating as a public limited company in the FMCG sector based in Karnataka, Karnataka, India. It was incorporated on 22 September 1988 and is registered under CIN L02411KA1988PLC009465. Listed on BSE: 532660 and NSE: VIVIMEDLAB. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Vivimed Labs Limited reported revenue of ₹69.99 Cr for FY 2025-26 (down 39.8% YoY) based on consolidated financials.
The current directors of Vivimed Labs Limited are:
- Manohar Rao Varalwar - Whole-Time Director
- Sandeep Varalwar - Whole-Time Director
- Santosh Varalwar - Managing Director
- Aparna Bidarkar - Director
- Siva Prasad Jarugula - Director
- Subbarathnamma Palepu - Director
The CIN (Corporate Identification Number) of Vivimed Labs Limited is L02411KA1988PLC009465. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Vivimed Labs Limited is listed on both BSE (code: 532660) and NSE (symbol: VIVIMEDLAB).